Compare CBAN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | ALT |
|---|---|---|
| Founded | 1975 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.3M | 421.5M |
| IPO Year | 1995 | 2005 |
| Metric | CBAN | ALT |
|---|---|---|
| Price | $20.80 | $3.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 249.0K | ★ 2.5M |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | 16.91 | ★ 25.37 |
| EPS | ★ 1.59 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $35.41 | N/A |
| Revenue Next Year | $4.84 | N/A |
| P/E Ratio | $13.20 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $14.54 | $2.87 |
| 52 Week High | $21.46 | $7.73 |
| Indicator | CBAN | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 51.91 |
| Support Level | $15.96 | $3.40 |
| Resistance Level | $21.27 | $3.54 |
| Average True Range (ATR) | 0.37 | 0.17 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 74.28 | 96.32 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.